Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858), a China-based pharmaceutical company, has announced receiving clinical trial approval for its investigational injectable product BC001. The drug is intended for use in combination with pucotenlimab for the treatment of advanced solid tumors, including first-line HER-2 negative advanced or metastatic gastric cancer/adenocarcinoma at the gastroesophageal junction (GC/GEJ). The drug will also be assessed in combination with chemotherapy.
BC001: A Monoclonal Antibody Targeting VEGFR2
The Category 1 biologic product, BC001, is a monoclonal antibody that targets vascular endothelial growth factor receptor 2 (VEGFR2). It is under development for the treatment of gastric cancer, non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and other solid tumors. BC001 is currently in a Phase III clinical study for second-line GC/GEJ treatment in combination with paclitaxel.
Comparative Market Context with Eli Lilly’s Cyramza
Eli Lilly’s Cyramza (ramucirumab), a similar product approved in China in March 2022, has been approved for the treatment of advanced GC/GEJ, metastatic NSCLC, metastatic CRC, and hepatocellular carcinoma. The approval of BC001 for clinical trials positions Shandong Buchang Pharmaceuticals to contribute to the growing field of targeted cancer therapies.-Fineline Info & Tech
